Tumor microenvironment phenotyping guides precision therapy in unresectable pancreatic cancer

Figure 1 Pancreatic cancer tumor microenvironment and multidimensional therapeutic strategy. AG: Gemcitabine plus nab-paclitaxel; Treg: Regulatory T cell; PEGPH20: Pegylated recombinant human hyaluronidase PH20; PD-1: Programmed cell death protein 1; myCAF: Myofibroblastic cancer-associated fibroblast; PDAC: Pancreatic ductal adenocarcinoma.

Figure 2 Four-dimensional tumor microenvironment phenotypic framework for locally advanced pancreatic cancer and its corresponding treatment strategies. LAPC: Locally advanced unresectable pancreatic cancer; SHG: Second-harmonic generation microscopy; CD: Cluster of differentiation; AG: Gemcitabine plus nab-paclitaxel; PEGPH20: Pegylated recombinant human hyaluronidase PH20; ABCi: Adenosine triphosphate-binding cassette inhibitor; PD-1: Programmed cell death protein 1; IDO1: Indoleamine 2,3-dioxygenase 1; SPARC: Secreted protein acidic and rich in cysteine; WT: Wild type; HRD: Homologous recombination deficiency; PARP: Poly adenosine diphosphate-ribose polymerase; CA: Carbohydrate antigen; ctDNA: Circulating tumor DNA; VAF: Variant allele frequency; CT: Computed tomography; TME: Tumor microenvironment.